Organs anatomy)

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

Retrieved on: 
Monday, September 6, 2021

Peijia Medical was founded in 2012 and its headquarter is based in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020. With "Devotion to the Heart, Reverence for Life" as its vision, Peijia Medical always puts life and safety in the first place, striving to maintain human life and health from its years of exploration in technology and its innovative persistence. Peijia Medical's strategic layout can be summarized as the "Innovation-oriented, Simultaneous Treatment of Cardiovascular and Cerebrovascular Diseases". It is dedicated to the innovation, R&D and production of high-end medical devices for structural heart disease and cerebrovascular interventions--covering aortic valve, mitral valve, tricuspid valve, surgical accessories, and diseases related to hemorrhage, ischemia and pathways in cerebrovascular intervention. It has built a relatively comprehensive array of product and solution portfolios in the field of structural heart disease and cerebrovascular interventions for use throughout China.

Key Points: 
  • Dr. Kar currently serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System, and Professor of Medicine at the David Geffen School of Medicine at UCLA.
  • He is recognized as the leading physician in developing and implementing minimally-invasive techniques in structural heart disease interventions.
  • Dr. Kar receives research grants from and is a consultant to multinational companies, such as Boston Scientific Corporation, Gore & Associates, and Abbott Vascular.
  • Peijia Medical was founded in 2012 and its headquarter is based in Suzhou,Jiangsu Province,China.

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

Retrieved on: 
Monday, September 6, 2021

Peijia Medical was founded in 2012 and its headquarter is based in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020. With "Devotion to the Heart, Reverence for Life" as its vision, Peijia Medical always puts life and safety in the first place, striving to maintain human life and health from its years of exploration in technology and its innovative persistence. Peijia Medical's strategic layout can be summarized as the "Innovation-oriented, Simultaneous Treatment of Cardiovascular and Cerebrovascular Diseases". It is dedicated to the innovation, R&D and production of high-end medical devices for structural heart disease and cerebrovascular interventions--covering aortic valve, mitral valve, tricuspid valve, surgical accessories, and diseases related to hemorrhage, ischemia and pathways in cerebrovascular intervention. It has built a relatively comprehensive array of product and solution portfolios in the field of structural heart disease and cerebrovascular interventions for use throughout China.

Key Points: 
  • Dr. Kar currently serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System, and Professor of Medicine at the David Geffen School of Medicine at UCLA.
  • He is recognized as the leading physician in developing and implementing minimally-invasive techniques in structural heart disease interventions.
  • Dr. Kar receives research grants from and is a consultant to multinational companies, such as Boston Scientific Corporation, Gore & Associates, and Abbott Vascular.
  • Peijia Medical was founded in 2012 and its headquarter is based in Suzhou,Jiangsu Province,China.

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Retrieved on: 
Wednesday, August 4, 2021

We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.

Key Points: 
  • We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.
  • The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth.
  • All participants entered the study with at least 50 percent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score.
  • This randomized, placebo-controlled, double-blind study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718).

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021

Management will also be available for 1x1 meetings onTuesday, August 10th Wednesday, August 11th, 2021.

Key Points: 
  • Management will also be available for 1x1 meetings onTuesday, August 10th Wednesday, August 11th, 2021.
  • Allena Pharmaceuticals, Inc.is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders.
  • Allenas lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
  • Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program planned for the second half of 2021.

Avalife Is Supporting the Brain Through the Stomach

Retrieved on: 
Tuesday, August 3, 2021

In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.

Key Points: 
  • In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.
  • A growing body of research has revealed how closely the brain and the gut work together a phenomenon known as the "gut-brain axis."
  • About Avalife: Avalife's parent company, Avacare Global, was founded by Dr. Vikram Naik in South Africa in 1997.
  • Avacare is the company's division that is focused on holistic solutions and targets natural and complementary medicine in pursuit of that end.

Can a vitamin treat COVID-19-related acute kidney injury?

Retrieved on: 
Monday, August 2, 2021

The randomized study will test the safety of nicotinamide riboside in hospitalized COVID-19 patients and if a biomarker relevant to acute kidney injury will be improved with the study treatment.

Key Points: 
  • The randomized study will test the safety of nicotinamide riboside in hospitalized COVID-19 patients and if a biomarker relevant to acute kidney injury will be improved with the study treatment.
  • "The potential benefit for patients enrolled in this study would be less kidney injury and preservation of kidney function," Dr. Sharma said.
  • "Our goal is to reduce the severity of acute kidney disease in patients with COVID-19 and potentially other types of acute kidney disease."
  • Acute kidney injury, which is reversible, is sudden loss of kidney function.

MatriSys Bioscience to Present at the 4th Microbiome Movement Skin Health & Dermatology Summit

Retrieved on: 
Thursday, July 29, 2021

LA JOLLA, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the companys CEO, Philippe Calais, Pharm.D., Ph.D., will present at the 4th Microbiome Movement Skin Health & Dermatology Summit, which will be held virtually August 3-5, 2021.

Key Points: 
  • LA JOLLA, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the companys CEO, Philippe Calais, Pharm.D., Ph.D., will present at the 4th Microbiome Movement Skin Health & Dermatology Summit, which will be held virtually August 3-5, 2021.
  • MatriSys Bioscience is leading the discovery and clinical development of a novel class of biopharmaceuticals to transform the treatment of inflammatory skin diseases.
  • Our groundbreaking technology platform identifies beneficial bacteria derived from healthy human skin to treat the millions of children and adults suffering from difficult to treat chronic skin diseases.
  • In addition to our lead clinical program in patients with atopic dermatitis, we are also rapidly advancing therapeutics for acne and rosacea.

Acute On Chronic Liver Failure (ACLF) Epidemiology Forecast Research Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021

The "Acute On Chronic Liver Failure (ACLF) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute On Chronic Liver Failure (ACLF) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Acute-On-Chronic Liver Failure ACLF)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Acute-On-Chronic Liver Failure (ACLF), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Acute-On-Chronic Liver Failure (ACLF) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Acute-On-Chronic Liver Failure (ACLF) epidemiology segmented as the Total Cases of Acute-On-Chronic Liver Failure (ACLF), Cases of Acute-On-Chronic Liver Failure (ACLF) by Grades, Organ Failure Associated with Acute-On-Chronic Liver Failure, Potential participating events of Acute-On-Chronic Liver Failure.

Global Graves Ophthalmopathy Market to 2030 - Insight, Epidemiology and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 22, 2021

The "Graves Ophthalmopathy - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Graves Ophthalmopathy - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Graves Ophthalmopathy market report provides current treatment practices, emerging drugs, Graves Ophthalmopathy market share of the individual therapies, current and forecasted Graves Ophthalmopathy market Size from 2017 to 2030 segmented by seven major markets.
  • The Graves Ophthalmopathy market report gives a thorough understanding of the Graves Ophthalmopathy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
  • The Graves Ophthalmopathy epidemiology division provide insights about historical and current Graves Ophthalmopathy patient pool and forecasted trend for every seven major countries.

Renalytix Appoints Joseph Hutson Vice President of Global Quality and Regulatory

Retrieved on: 
Thursday, July 22, 2021

The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).

Key Points: 
  • The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).
  • Each year, kidney disease kills more people than breast and prostate cancer.
  • Every day, 13 patients in the United States die while waiting for a kidney transplant.
  • Words such as anticipates, believes, estimates, expects, intends, plans, seeks, and similar expressions are intended to identify forward-looking statements.